Business Context and Reporting Period
This Form 8-K is a current report filed by Oncocyte Corporation (trading symbol: OCX) on November 3, 2022. The filing addresses corporate governance changes effective as of the report date. Note: The request metadata references "Insight Molecular Diagnostics Inc.," but the filing text explicitly identifies the registrant as Oncocyte Corporation.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on amendments to corporate bylaws and does not contain financial statements or performance metrics.
Material Changes
The Board of Directors approved and adopted the Second Amended and Restated Bylaws. The primary material change allows the Company to appoint a President or Presidents without requiring that the Chief Executive Officer also hold the title of President.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. The document is limited to the procedural adoption of new bylaws.
Key Facts for Investor Verification
- The registrant is Oncocyte Corporation, not Insight Molecular Diagnostics Inc.
- Effective November 3, 2022, the Company's Bylaws were amended to decouple the roles of CEO and President.
- The full text of the Second Amended and Restated Bylaws is available as Exhibit 3.1.
- No financial data or operational updates are included in this specific filing.